IP Library › Granted Patent US 9,987,225
Granted Patent B2
US 9,987,225 · App. 13/499,088 · Granted Jun 5, 2018

Crosslinked hydrogels and related method of preparation

Inventors: May Griffith (Carp, CA); Fengfu Li (Gloucester, CA); Jae-Il Ahn (Ottawa, CA)
Assignee: Ottawa Hospital Research Institute
A61K9/06A61K9/0051A61K31/522A61K41/0042A61K47/42A61L27/24A61L27/52C08H1/06C08J3/075C08J3/24C08K5/0025C08K5/29C08L89/06A61K38/39A61K49/0073A61L2430/16C08J2300/16C08J2389/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,987,225
App. No.
13/499,088
Granted
Jun 5, 2018
Kind
B2
Abstract

The present invention provides a method of manufacturing a hydrogel comprising the step of crosslinking a biopolymer using a carbodiimide crosslinker of Formula I wherein at least one of R 1 and R 2 is a functional group that is a bulky organic functional group. R 1 and R 2 can each independently be an optionally substituted saturated or unsaturated functional group selected from the group consisting of an alkyl, a cycloalkyl, a heterocyclic, and an aryl. The bulky organic functional group will slow down the crosslinking reaction of carbodiimide due to the steric effects and/or electronic effects, in comparison to a crosslinking reaction using EDC. Also provided are the hydrogels and ophthalmic devices prepared using the method of the invention and uses thereof.

Claims (11)

1. A method of manufacturing a hydrogel having a white light transmission of at least 70%, the method comprising:

a) mixing at room temperature a collagen and a carbodiimide crosslinker, wherein the carbodiimide crosslinker is (N-Cyclohexyl-N′-(2-morpholinoethyl)carbodiimide) (CMC) or a metho-p-toluenesulfonate salt thereof,

and the molar equivalent ratio of carbodiimide crosslinker to collagen amine groups is from about 0.3 to about 0.7; and

b) casting the mixture into a mold prior to gelation, wherein the time to gelation at room temperature is increased relative to use of the crosslinker 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide (EDC).

2. The method of claim 1 , wherein the carbodiimide crosslinker is water soluble.

3. The method of claim 1 , wherein the collagen is recombinant human type III collagen.

4. The method of claim 1 , wherein the hydrogel is a composite additionally comprising a water-soluble acrylic, methacrylic, or acrylamide.

5. The method of claim 4 , wherein the water-soluble acrylic, methacrylic, or acrylamide is one or more of MPC (2-methacryloyloxyethyl phophorylcholine) and PEG-DA (polyethylene glycol-diacrylate).

6. The method of claim 1 , wherein prior to mixing, the collagen is treated to photo polymerization.

7. The method of claim 1 , wherein the molar equivalent ratio of carbodiimide crosslinker to collagen amine groups is about 0.5.

8. The method of claim 1 , wherein gelation time is 2.5- to 4-fold longer compared to crosslinking using EDC.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2012
From: GRIFFITH, MAY; LI, FENGFU; AHN, JAE-IL
To: OTTAWA HOSPITAL RESEARCH INSTITUTE; UNIVERSITY OF OTTAWA
Reel/Frame 028180/0603 →
Continuity (2)
Provisional Application 61247391 · Sep 30, 2009
Related Publication 20120321585A1 · Dec 20, 2012